NERV - Minerva Neurosciences, Inc.
| Previous Close | 8.16 |
| Open | 8.19 |
| Bid | 8.37 x 1400 |
| Ask | 8.40 x 1000 |
| Day's Range | 8.36 - 8.29 |
| 52 Week Range | 5.80 - 12.95 |
| Volume | 75,992 |
| Avg. Volume | 140,635 |
| Market Cap | 331.326M |
| Beta (3Y Monthly) | 1.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Thomson Reuters StreetEvents•5 days ago
Edited Transcript of NERV earnings conference call or presentation 12-Mar-19 12:30pm GMT
Q4 2018 Minerva Neurosciences Inc Earnings Call
Motley Fool•6 days agoMinerva Neurosciences Inc (NERV) Q4 2018 Earnings Conference Call Transcript
NERV earnings call for the period ending December 31, 2018.
- Associated Press•6 days ago
Minerva Neurosciences: 4Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of 34 cents per share. For the year, the company reported that its loss widened to $50.2 million, or $1.29 per share. Minerva Neurosciences shares ...
- Simply Wall St.•3 months ago
How Much Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Do Institutions Own?
Every investor in Minerva Neurosciences, Inc. (NASDAQ:NERV) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see Read More...
- Zacks•4 months ago
Minerva Neurosciences Sees Hammer Chart Pattern: Time to Buy?
Minerva Neurosciences has been struggling lately, but the selling pressure may be coming to an end soon.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of NERV earnings conference call or presentation 5-Nov-18 1:30pm GMT
Q3 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•4 months ago
Minerva Neurosciences: 3Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 31 cents. Minerva Neurosciences shares have risen 93 percent since the beginning of the year. The stock has increased ...
- Simply Wall St.•5 months ago
Minerva Neurosciences Inc (NASDAQ:NERV): Risks You Need To Consider Before Buying
If you own shares in Minerva Neurosciences Inc (NASDAQ:NERV) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- Zacks•6 months ago
J&J Submits NDA to the FDA for Depression Drug in Adults
Johnson & Johnson (JNJ) submits NDA to the FDA for esketamine nasal spray seeking approval for treatment-resistant depression in adults in the United States.
- Benzinga•7 months ago
The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 22) Acer Therapeutics Inc (NASDAQ: ACER ) Avanos Medical Inc (NYSE: ...
- Thomson Reuters StreetEvents•7 months ago
Edited Transcript of NERV earnings conference call or presentation 2-Aug-18 12:30pm GMT
Q2 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•7 months ago
Minerva Neurosciences: 2Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of 32 cents per share. Minerva Neurosciences shares have climbed 32 percent since the beginning of the year. The stock has increased 13 percent ...
- Thomson Reuters StreetEvents•10 months ago
Edited Transcript of NERV earnings conference call or presentation 3-May-18 12:30pm GMT
Q1 2018 Minerva Neurosciences Inc Earnings Call
- Zacks•last year
Will Minerva Neurosciences (NERV) Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Minerva Neurosciences, Inc. (NERV).
